Remegen Co., Ltd.

This study tested whether a weekly injection called telitacicept could safely reduce disease activity in people with active primary Sjogren's syndrome, an autoimmune condition causing severe dryness and fatigue. For 48 weeks, 381 adults received either the drug at one of two dose…

This early-stage study tested a new drug called RC88 in 198 patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and see if the drug showed any early signs of slowing cancer growth. The study focused on ca…

This early-stage study tested a new cancer drug called RC108-ADC in 67 patients with advanced solid tumors that had a specific marker (c-Met positive). The main goals were to find the highest safe dose and check for side effects. Researchers also measured how the drug moved throu…

This early-stage study tested how a drug called telitacicept behaves in the bodies of children with lupus. Sixteen young patients received the drug alongside their standard lupus treatments. Researchers primarily measured drug levels in the blood and also checked for safety and e…

This study tested an experimental drug called RC88 in women whose ovarian, fallopian tube, or primary peritoneal cancer had returned and was no longer responding to standard platinum-based chemotherapy. The main goals were to see if the drug could shrink tumors, how long the bene…

This study tested an experimental drug called RC108 in patients with advanced cancers of the digestive system, such as stomach, colon, liver, or pancreatic cancer, whose tumors had a specific marker called c-Met. The main goals were to see if the drug could shrink tumors, how saf…

This study allowed patients with advanced solid tumors who had already tried RC88 in earlier research to continue receiving the treatment while researchers monitored its safety. The main goal was to find the safest and most effective dose and see how well patients tolerated the d…